Praxis Precision Medicines (PRAX) reported positive trial results late Thursday of relutrigine to treat patients with SCN2A and SCN8A developmental and epileptic encephalopathies.

Deutsche Bank adjusted its price target for Praxis shares to $303 from $270 while maintaining its buy rating.

Praxis shares soared 31% as intraday trading volume surged to over 2.2 million from a daily average of roughly 975,000.

SoftBank Group is in talks to buy private-equity firm DigitalBridge Group (DBRG), Bloomberg reported Friday, citing people with knowledge of the matter.

Shares of DigitalBridge surged 39% as intraday trading volume catapulted to over 22.4 million from a daily average of about 3.3 million.

Perceptive Capital Solutions (PCSC), a special-purpose acquisition company, and biotech firm Freenome said Friday that they have agreed to form a business combination.

The companies said the deal includes commitments from a group of healthcare investors for a $240 million common equity Private Investment in Public Equity at $10 per share.

Shares of Perceptive Capital jumped 12% as intraday trading volume climbed to nearly 2.3 million from a daily average of about 3,000.

Price: 248.34, Change: +58.37, Percent Change: +30.73